MRF Publication News is a trusted platform that delivers the latest industry updates, research insights, and significant developments across a wide range of sectors. Our commitment to providing high-quality, data-driven news ensures that professionals and businesses stay informed and competitive in today’s fast-paced market environment.
The News section of MRF Publication News is a comprehensive resource for major industry events, including product launches, market expansions, mergers and acquisitions, financial reports, and strategic partnerships. This section is designed to help businesses gain valuable insights into market trends and dynamics, enabling them to make informed decisions that drive growth and success.
MRF Publication News covers a diverse array of industries, including Healthcare, Automotive, Utilities, Materials, Chemicals, Energy, Telecommunications, Technology, Financials, and Consumer Goods. Our mission is to provide professionals across these sectors with reliable, up-to-date news and analysis that shapes the future of their industries.
By offering expert insights and actionable intelligence, MRF Publication News enhances brand visibility, credibility, and engagement for businesses worldwide. Whether it’s a ground breaking technological innovation or an emerging market opportunity, our platform serves as a vital connection between industry leaders, stakeholders, and decision-makers.
Stay informed with MRF Publication News – your trusted partner for impactful industry news and insights.
Industrials

In a significant move to bolster its presence in the global healthcare landscape, Amgen Inc. (AMGN) has announced an initial investment of $200 million to establish a cutting-edge technology and innovation center in Hyderabad, India. This strategic initiative underscores Amgen's commitment to harnessing artificial intelligence (AI) and data science to accelerate drug discovery and development, aligning with the company's broader vision of enhancing operational efficiency and expediting the delivery of innovative therapies worldwide.
Located in HITEC City, Hyderabad, the new center will serve as a hub for AI-driven innovations, supporting the development of groundbreaking medicines. The site, which spans approximately 524,000 square feet in RMZ Tower 110 and Tower 20 of Nexity, is designed to leverage India's robust talent pool and cost-effective innovation ecosystem. This move not only solidifies Hyderabad's position as a burgeoning biotech hub but also underscores India's strategic importance in shaping the future of biopharmaceutical advancements.
Amgen's investment is a testament to India's growing prominence as a hub for healthcare innovation. The country, often referred to as the "pharmacy of the world," has been strengthening its life sciences ecosystem, positioning itself as a preferred destination for global healthcare investments. This initiative aligns with the U.S.-India Trust Initiative, aimed at promoting collaboration in emerging technologies like AI and biotechnology.
Looking ahead, Amgen plans to expand its footprint in India further, with additional investments aimed at fostering innovation and boosting healthcare outcomes. The company's focus on AI-driven drug development will not only streamline R&D processes but also ensure faster access to breakthrough therapies for patients in India and globally. This strategic move mirrors similar initiatives by global pharmaceutical leaders like Pfizer, Novartis, and Eli Lilly, which have also invested in Indian technology centers to leverage the country's robust talent pool and cost-effective innovation ecosystem.
Amgen's investment in India marks a significant milestone in the company's journey to harness technology across its global network. By leveraging AI and data science, Amgen aims to enhance its medicine pipeline and better serve patients worldwide. As India continues to emerge as a global healthcare innovation hub, Amgen's strategic move underscores the country's strategic importance in shaping the future of biopharmaceutical advancements.